Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML

Cell Reports(2024)10.1016/j.celrep.2024.114901Source: DataRank Database

NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML is a research paper published in Cell Reports (2024). On theSindex it has a DataRank of 0.422. It has been cited 12 times, with 7 citing works in its 1-hop citation network.

N/A

0.422DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access12 citations · 7 citing works in its network

Download PDF

Cite:

Linked data & code

geo nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

GEOGSE249218

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 2.26)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 91%Citation Network 9%

Base Score Contribution

0.385

From this paper's citation signal

Citation Network Contribution

0.0376

From 3 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 7 citers.

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies
Leukemia Research20255 citations93 referencesContributes 0.019
Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia
Cancers20259 citations129 referencesContributes 0.018
Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy
npj Precision Oncology20253 citations195 referencesContributes 0.007
Acute Leukemia in the Crosshairs: First‐in‐Class Menin Inhibitor Approval for Adults and Children
Pediatric Blood & Cancer20250 citations39 referencesContributes 0.000
Preferential formation of NUP98-KDM5A condensates at specific H3K4me3-rich loci drives leukemogenic gene expression
bioRxiv (Cold Spring Harbor Laboratory)20260 citations65 referencesContributes 0.000

Authors (11)

Cynthia Martucci ORCID,Jill A. Henrich,Dana S. Neel ORCID,Sanisha Mahendra-Rajah,Hannah Rice

Live enrichment

PubMed:39475509 PMC:PMC11780541 OpenAlex:https://openalex.org/W4403911211

German Research Foundation

Grant: 528168324

German Research Foundation

Grant: 511811315

California Department of Fish and Game

Grant: PE 3217/2-1

California Department of Fish and Game

Grant: PE 3217/4-1

National Cancer Institute

Grant: CA243124

National Cancer Institute

Grant: NIH 5 P30 CA06516

National Cancer Institute

Grant: CA066996

NCI NIH HHS

Grant: U54 CA243124

NCI NIH HHS

Grant: P30 CA006516

NCI NIH HHS

Grant: K08 CA279891

NCI NIH HHS

Grant: P01 CA066996

National Institutes of Health

Grant: 5K08CA279891-02

Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia

National Institutes of Health

Grant: 1U54CA243124-01

Experimental and preclinical modeling of NUP98-rearranged acute leukemia

National Institutes of Health

Grant: 3P30CA006516-41S6

CANCER CENTER SUPPORT GRANT

National Institutes of Health

Grant: 1P01CA066996-03

BIOLOGICAL HETEROGENEITY OF AGGRESSIVE NONHODGKINS LYMPHOMA

American Society of Hematology

Else Kröner-Fresenius-Stiftung

Harvard Medical School

National Institutes of Health

Children's Cancer Research Fund

Dana-Farber Cancer Institute

Hyundai Hope on Wheels

FWCI

2.26

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.celrep.2024.114901

publisherhttps://doi.org/10.1016/j.celrep.2024.114901

publisherhttps://api.elsevier.com/content/article/PII:S221112472401252X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S221112472401252X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39475509

Fields of Study

Protein Degradation and InhibitorsAcute Myeloid Leukemia ResearchRNA modifications and cancer0301 basic medicine03 medical and health sciences

MeSH Terms

AnimalsChromatinHumansHistone-Lysine N-MethyltransferaseProto-Oncogene ProteinsLeukemia, Myeloid, AcuteOncogene Proteins, FusionGene Expression Regulation, LeukemicNuclear Pore Complex ProteinsCell Line, TumorMiceMyeloid-Lymphoid Leukemia ProteinPolycomb Repressive Complex 1

Keywords

Fusion proteinGeneFusion geneGene expressionBiologyCancer researchCell biologyGeneticsAcute myeloid leukemiaMeninChromatin ComplexOncogenic Fusion ProteinNascent TranscriptomicsCp: Molecular BiologyCp: CancerLysine Methyltransferase 2ANucleoporin 98-RearrangementNon-canonical Polycomb Repressive Complex 1.1Polycomb Repressive Complex 1Oncogene Proteins, FusionGene Expression Regulation, LeukemicHistone-Lysine N-MethyltransferaseArticleChromatinNuclear Pore Complex ProteinsLeukemia, Myeloid, AcuteMiceProto-Oncogene ProteinsCell Line, TumorHumansAnimalsMyeloid-Lymphoid Leukemia Protein

NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (11)

Funding (22 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)